Market Overview

Endo Health, Metamark Announce Sale of HealthTronics Lab Solutions, No Terms Disclosed

Related ENDP
Jazz Pharmaceuticals (JAZZ) in Focus: Stock Surges 8.8% - Tale of the Tape
Jazz Pharmaceuticals (JAZZ) Jumps: Stock Moves 5.2% Higher - Tale of the Tape

Endo Health Solutions (Nasdaq: ENDP) today announced that its wholly owned subsidiary, HealthTronics, Inc. has entered into a definitive agreement to sell its anatomical pathology business, HealthTronics Laboratory Solutions, Inc., ("HLS") to Metamark Genetics, Inc. ("Metamark") for an undisclosed amount.   As previously announced Endo Health Solutions is pursuing strategic alternatives for HealthTronics, Inc. and believes the sale of HLS creates progress in this process.  

Metamark is at the leading edge of research in cancer prognosis, which is a critical tool in determining appropriate cancer therapy. In the age of personalized medicine, particularly in oncology, Metamark's proprietary multiplex proteomic platform has the potential to reshape the landscape in cancer diagnosis and therapy.

HLS provides anatomical pathology services primarily to the urology community. The HLS pathology labs are located in Georgia and Pennsylvania and provide laboratory and diagnostic services to urologists throughout the U.S., with client practices in 41 states.  In addition, HLS manages pathology laboratories for physician practice groups, provides administrative services to in-office pathology labs for practice groups, and provides pathology services to physicians.

Posted-In: News Asset Sales M&A

 

Related Articles (ENDP)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters